

PolyMedix is focused on **developing novel, first in class therapeutic drugs for the treatment of acute cardiovascular disorders and infectious diseases**. We have created a robust product pipeline using the *proprietary computational technology platform* that we licensed from the University of Pennsylvania. **Our first two clinical products entering Phase 2 clinical trials are PMX-60056, a unique anticoagulant reversing agent and PMX-30063, a novel small molecule defensin mimetic antibiotic**. Both products have demonstrated proof of concept, and are the first and only ones of their kind.

PolyMedix's product opportunities have been **rationally selected to mitigate risk**:

- Fast clinical trials – acute dosing (single dose to days), plus the possibility of accelerated development paths.
- Straightforward endpoints, *to easily determine if the drug works*.
- Indications where animal models and Phase I clinical data are generally considered predictive of success.
- Address major market opportunities.

Product Pipeline (timelines assume adequate financing)

	Indication	Pre-Clinical	Phase 1	Phase 2	Phase 3
PMX-60056*	Heparin / LMWH antagonist	→		→ 2010	
PMX-30063	Defensin-mimetic antibiotic (IV)	→		→ 2010	
Other Pipeline Opportunities					
PMX-30063	Defensin-mimetic antibiotic (oral, topical)	→			
PMX-50003	Polymer biomaterials	→			
PMX-70004		→			
PMX-10072	Anti-tuberculosis	→			
PMX-30024	Anti-malaria	→			
PMX-10098	Anti-fungal	→			
PMX-30016	Biodefense	→			
PMX-20005	Angiogenesis inhibitor	→			


* PMX-60056 efficacy has been demonstrated in Phase 1B in normal subjects

Using our proprietary computational drug design technologies, we have developed a **sustainable, full pipeline of novel biomimetic drugs for acute, serious, life-threatening disorders**.

PMX-60056 - Heptagonist

PMX-60056, is a synthetic, small molecule designed to reverse the anticoagulant activity of heparin and low molecular weight heparin (LMWH). In cardiothoracic and orthopedic surgical procedures, heparin is administered to prevent blood clots from forming. After surgery, the anticoagulant activity of heparin must be reversed in order to restore normal clot formation and to avoid the risk of potentially life-threatening uncontrolled bleeding. Currently, the only agent available to reverse heparin is protamine which has many limitations. To prevent the formation of blood clots in patients with deep vein thrombosis, undergoing cancer treatments or after hip replacement surgeries and heart attacks, LMWHs are used. Approximately 12 million patients use LMWHs annually for chronic treatment of thrombosis, and up to 20% may experience clinically significant bleeding complications. There is no FDA approved product available to reverse the anticoagulant activity of LMWHs.

PMX-60056 neutralized both heparin and LMWH and normalized clotting time in three pilot efficacy clinical trials



PolyMedix is developing PMX-60056 as an alternative to protamine for reversing heparin and as the first and only product to reverse LMWHs.


Results from two Phase 1B/2 double-blind, placebo controlled efficacy studies to reverse both heparin and LMWH showed that PMX-60056 was safe and well-tolerated with no serious adverse effects. In a dose-ranging Phase 1B/2 study, PMX-60056 reversed surgical levels of heparin and allowed for re-anticoagulation. Pre-clinical and clinical data suggest potential safety and other advantages over protamine, as well as a unique opportunity to be the first reversing agent for LMWHs. PolyMedix is planning to initiate a Phase 2 clinical trial in surgical patients in 2010.

PMX-30063 - Antibiotic

Infections are the leading cause of death, with over 14.2 million MRSA cases annually in the U.S. 70% of infections are now drug resistant, and one of the most serious medical problems in the world today. The world anti-infective drug market is approximately \$36 billion and growing due to the rapid rise of drug resistant bacterial infections, a risk with any conventional biochemical antibiotic approach.

PolyMedix *imitated nature* and mimicked the *activity and structure of host defense proteins*, one of the oldest and most effective antimicrobial defense systems in virtually all living creatures. We believe PMX-30063 is the only small molecule mimetic of host defense proteins under development for systemic use.

PMX-30063 Directly Targets and Disrupts Membrane from Outside



Primitive life forms such as molds secrete compounds like tetracycline and penicillin to protect themselves from bacteria.

Many forms of life produce host defense proteins as their first line of defense against bacteria.

Despite hundreds of millions of years of evolution, widespread bacterial resistance has not developed to the host defense proteins, validating this antimicrobial mechanism of action and target for the development of new antibiotic drugs.

PMX-30063 Features

- Novel mechanism of action – physically disrupting bacterial cell membranes – *makes resistance unlikely to develop.*
- Potent activity against 100's of Gram-positive and Gram-negative bacteria, **including 398 strains of Staph and MRSA.**
- Much faster bactericidal action than other antibiotics, *seconds to minutes vs. days.*
- Proven activity against drug-resistant bacteria, including multiple MRSA, VRSA and VRE strains.
- Additional formulations and applications – ophthalmic, oral and topical.

Phase 1 results demonstrate safe administration of PMX-30063 (in single or divided doses), at doses that exceeded theoretical efficacious levels predicted by animal models. In addition, PMX-30063 killed Staph bacteria, including MRSA, in human serum in blood samples drawn from subjects in the study. Side effects were seen only at higher doses and were all mild and fully reversible. PolyMedix is planning to start a Phase 2 efficacy study in patients with Staph infections in 2010.

PolyMedix has raised over \$90 million since being founded in 2002, including 13 approved SBIR grants and research contracts.

Experienced management team

- *President & C.E.O. - Nicholas Landekic*
- *Vice President Clinical Development – Dr. Eric McAllister*
- *Vice President Drug Development – Dr. Bozena Korczak*
- *Vice President Research – Dr. Richard Scott*
- *Vice President Finance & C.F.O. – Edward Smith*

Renowned Scientific Founders

From the University of Pennsylvania, members of the National Academy of Sciences, American Academy of Arts and Sciences, and the Royal Society:

- *Dr. William DeGrado*
- *Dr. Michael Klein*
- *Dr. Gregory Tew*

Contact PolyMedix for Additional Information:

Lisa Caperelli, Director Investor Relations & Corporate Communications

Ph: 484-598-2406

lcaperelli@polymedix.com

Informational materials on PolyMedix may contain forward-looking statements, including regarding anticipated scientific progress in research programs and product development. Developing drugs is risky, expensive, and time-consuming. Delays typically occur in drug development and should be expected, and the actual pace of PolyMedix's development may be substantially delayed and materially differ from these goals and projections. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements.